193 related articles for article (PubMed ID: 37989909)
21. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
[TBL] [Abstract][Full Text] [Related]
22. Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program.
Plutzky J; Benson MD; Chaney K; Bui TV; Kraft M; Matta L; McPartlin M; Zelle D; Cannon CP; Dodek A; Gaziano TA; Desai AS; MacRae CA; Scirica BM
Am Heart J; 2022 Jan; 243():15-27. PubMed ID: 34481756
[TBL] [Abstract][Full Text] [Related]
23. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis.
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
Atherosclerosis; 2015 Aug; 241(2):450-4. PubMed ID: 26074319
[TBL] [Abstract][Full Text] [Related]
24. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
[TBL] [Abstract][Full Text] [Related]
25. Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry.
De Luca L; Arca M; Temporelli PL; Meessen J; Riccio C; Bonomo P; Colavita AR; Gabrielli D; Gulizia MM; Colivicchi F;
Int J Cardiol; 2020 Oct; 316():229-235. PubMed ID: 32470532
[TBL] [Abstract][Full Text] [Related]
26. Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey.
Gupta K; Kakar TS; Jain V; Gupta M; Al Rifai M; Slipczuk L; Nambi V; Bittner V; Blumenthal RS; Stone NJ; Lavie CJ; Virani SS
Prog Cardiovasc Dis; 2022; 75():78-82. PubMed ID: 36038004
[TBL] [Abstract][Full Text] [Related]
27. Characterization and LDL-C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT-DYS study.
Gavina C; Seabra-Carvalho D; Aguiar C; Anastassopoulou A; Teixeira C; Ruivo JA; Almeida É; Luz-Duarte L; Corte-Real A; Canelas-Pais M; Taveira-Gomes T
Clin Cardiol; 2024 Jan; 47(1):e24183. PubMed ID: 37933175
[TBL] [Abstract][Full Text] [Related]
28. Guidelines impact cholesterol management.
Yu S; Zolfaghari K; Rascati KL; Copeland LA; Godley PJ; McNeal C
J Clin Lipidol; 2019; 13(3):432-442. PubMed ID: 30992244
[TBL] [Abstract][Full Text] [Related]
29. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
[TBL] [Abstract][Full Text] [Related]
30. Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002-2016.
Romanelli RJ; Ito MK; Karalis DG; Huang HC; Iorga ŞR; Kam IW; Thompson S; Azar KMJ
J Clin Lipidol; 2020; 14(3):305-314. PubMed ID: 32362513
[TBL] [Abstract][Full Text] [Related]
31. Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease.
Karalis DG
Curr Opin Lipidol; 2023 Dec; 34(6):252-258. PubMed ID: 37594008
[TBL] [Abstract][Full Text] [Related]
32. Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry.
Nanna MG; Navar AM; Wang TY; Li S; Virani SS; Li Z; Robinson JG; Roger VL; Wilson PWF; Goldberg AC; Koren A; Louie MJ; Peterson ED
Am Heart J; 2019 Aug; 214():113-124. PubMed ID: 31202098
[TBL] [Abstract][Full Text] [Related]
33. Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol.
Wong ND; Amsterdam EA; Ballantyne C; Khera A; Nasir K; Toth PP;
Am J Cardiovasc Drugs; 2020 Feb; 20(1):1-9. PubMed ID: 31286451
[TBL] [Abstract][Full Text] [Related]
34. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
[TBL] [Abstract][Full Text] [Related]
35. Frequency of high-risk patients not receiving high-potency statin (from a large managed care database).
Rodriguez F; Olufade T; Heithoff K; Friedman HS; Navaratnam P; Foody JM
Am J Cardiol; 2015 Jan; 115(2):190-5. PubMed ID: 25432414
[TBL] [Abstract][Full Text] [Related]
36. Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification.
Rana JS; Virani SS; Moffet HH; Liu JY; Coghlan LA; Vasadia J; Ballantyne CM; Karter AJ
Am J Med; 2022 May; 135(5):603-606. PubMed ID: 34861203
[TBL] [Abstract][Full Text] [Related]
37. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
[TBL] [Abstract][Full Text] [Related]
38. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
39. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
Shaik A; Kosiborod M; de Lemos JA; Gao Q; Mues KE; Alam S; Bhatt DL; Cannon CP; Ballantyne CM; Rosenson RS;
Clin Cardiol; 2022 Dec; 45(12):1303-1310. PubMed ID: 36124341
[TBL] [Abstract][Full Text] [Related]
40. Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A Survey of US Practice in the PALM Registry).
Lowenstern A; Navar AM; Li S; Virani SS; Goldberg AC; Louie MJ; Lee LV; Peterson ED; Wang TY
Am J Cardiol; 2019 Apr; 123(7):1011-1018. PubMed ID: 30660354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
